Showing results (181-190 of 201) with videos related to

Sort By:
Pageof 21
Journal of Immunology (Baltimore, Md. : 1950)|February 7, 2004
Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejectionNathalie Chaput, Nöel E C Schartz, Fabrice André, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2019
Angiotensin II receptor blockers, steroids and radiotherapy in glioblastoma-a randomised multicentre trial (ASTER trial). An ANOCEF studyR Ursu, L Thomas, D Psimaras, et al.
Scientific Reports|July 1, 2026
Long-term treatment outcomes of immune checkpoint inhibitor-related neuropathies: a French multicenter cohort studyStefania Cuzzubbo, Edouard Berling, Pierre Lozeron, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 25, 2003
European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiformeM J van den Bent, W Grisold, D Frappaz, et al.
Annals of Neurology|May 1, 2007
Dynamic history of low-grade gliomas before and after temozolomide treatmentDamien Ricard, Gentian Kaloshi, Alexandra Amiel-Benouaich, et al.
Scientific Reports|November 5, 2020
Description of neurotoxicity in a series of patients treated with CAR T-cell therapyCatherine Belin, Perrine Devic, Xavier Ayrignac, et al.
Annals of Neurology|July 29, 2005
Chromosome 1p loss: a favorable prognostic factor in low-grade gliomasMichèle Kujas, Julie Lejeune, Alexandra Benouaich-Amiel, et al.
Acta Neuropathologica Communications|January 4, 2022
Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary studyCarine Jiguet-Jiglaire, Sebastien Boissonneau, Emilie Denicolai, et al.
Nature Medicine|October 21, 2003
PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemiaRose Ann Padua, Jerome Larghero, Marie Robin, et al.
Neuro-Oncology|February 24, 2016
A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastomaAlba A Brandes, Antoine F Carpentier, Santosh Kesari, et al.
Pageof 21